Lp(a): What You Can Do Now – Current Insights and Future Directions in Cardiovascular Health-Lp(a): What You Can Do Now – Current Insights and Future Directions in Cardiovascular Health

Lp(a): What You Can Do Now – Current Insights and Future Directions in Cardiovascular Health

Video Transcription

Video Summary

The webinar, led by Dr. Erin Mekos from Johns Hopkins University and organized by the American College of Cardiology, focused on the current insights and future directions in managing lipoprotein(a) (LPA) levels to address cardiovascular risk. The webinar featured presentations by esteemed panelists, including Dr. Christy Ballantine, Dr. Josette Ray Sofer, Susan Hall Dimitri, and Dr. Steven Nissen. Dr. Ballantine provided an overview of LPA's genetic and epidemiological roles in cardiovascular risk, revealing its association with conditions like aortic valve stenosis and cardiovascular mortality. Screening for high LPA levels can help identify at-risk families and patients. Dr. Ray Sofer discussed risk assessment and highlighted under-testing in certain populations. Practical tools and calculators for evaluating cardiovascular risk were also introduced. Dr. Nissen elaborated on emerging treatments, including antisense oligonucleotides and small interfering RNA therapies, capable of significantly reducing LPA levels. The panelists emphasized managing traditional cardiovascular risk factors, encouraging lifestyle modifications, and considering advanced treatments like PCSK9 inhibitors for those with high LPA. The session also advocated for family screening due to LPA’s genetic nature and addressed varied approaches for primary and secondary prevention of cardiovascular events.

Keywords

Lipoprotein(a)

Cardiovascular risk

Genetic screening

Antisense oligonucleotides

Small interfering RNA

PCSK9 inhibitors

Aortic valve stenosis

Risk assessment tools

Lifestyle modifications